Skip to search formSkip to main contentSkip to account menu

oclacitinib

National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

PyrimidinesSulfonamides

Narrower (1)

oclacitinib maleate
oclacitinib maleate 5.4 MG Oral Tablet [Apoquel]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib.
OBJECTIVE To compare the cumulative incidences of malignancies and benign skin masses and the mean age at death or euthanasia in… 
Review
2018
Review
2018
A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA
BACKGROUND Lokivetmab neutralizes IL-31, a cytokine that plays an important role in the pathogenesis of atopic dermatitis (AD) in… 
2017
2017
The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study
BACKGROUND Oclacitinib is a selective Janus kinase inhibitor for the treatment of canine allergic pruritus and atopic dermatitis… 
Review
2016
Review
2016
An update on the treatment of canine atopic dermatitis.
Review
2015
Review
2015
Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
BACKGROUND Oclacitinib is safe and effective for treating dogs with pruritus associated with allergic and atopic dermatitis… 
Highly Cited
2015
Highly Cited
2015
Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)
BackgroundIn 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of… 
Highly Cited
2015
Highly Cited
2015
IL‐31‐induced pruritus in dogs: a novel experimental model to evaluate anti‐pruritic effects of canine therapeutics
Background Pruritus is a characteristic clinical sign of allergic skin conditions including atopic dermatitis (AD) in the dog. IL… 
Highly Cited
2014
Highly Cited
2014
A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs
Background Ciclosporin is approved for the treatment of atopic dermatitis (AD) in dogs and has been shown to be safe and… 
Highly Cited
2014
Highly Cited
2014
Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia
Background Oral glucocorticoids are widely used to reduce pruritus and dermatitis associated with allergic dermatitis. Data… 
Highly Cited
2013
Highly Cited
2013
A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis
Background Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Preliminary study results suggest that… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)